Maxim resumed coverage of Xtant Medical with a Buy rating and $1.50 price target. With the overall focus on the higher-growth and higher-margin orthobiologics business, Xtant is positioned for organic and profitable growth, and may engage in M&A, partnerships, or in-licensing deals, the analyst tells investors in a research note. Xtant is also currently self-financing and does not require a capital raise to continue operations, the firm added.
